>
>
Antibody Therapy Market - By Type [Monoclonal Antibodies (mAbs) {Oncology, Autoimmune Disease, Infectious Disease}, Antibody-drug Conjugates (ADCs)], By End-use (Hospitals, Specialty Centers) – Global Forecast, 2023 – 2032
Download Free PDF

Antibody Therapy Market
Get a free sample of this reportGet a free sample of this report Antibody Therapy Market
Is your requirement urgent? Please give us your business email for a speedy delivery!
Buy Now
$4,123 $4,850
15% off
$4,840 $6,050
20% off
$5,845 $8,350
30% off
Buy now
Premium Report Details
Base Year: 2022
Companies covered: 13
Tables & Figures: 219
Countries covered: 24
Pages: 150
Download Free PDF
Antibody Therapy Market Size
Antibody Therapy Market size accounted for USD 214.7 billion in 2022 and is projected to expand at 11.8% CAGR from 2023 to 2032. The industry is experiencing exponential growth from the last few years as new therapies and drugs have been approved for the treatment of diseases. To date, the Food and Drug Administration (FDA) has approved more than 100 antibody products and every year around a fifth of new drug approvals are of biologics. The presence of a healthy antibody therapy pipeline creates a high potential for the company to attain larger market revenue.
Antibody therapy is a targeted therapeutic intervention comprising concentrated or monoclonal antibody used to manage diseases such as cancer/oncology, infectious diseases and autoimmune diseases among other diseases. These therapeutic antibodies bind to specific molecules on the surface of cells, triggering immune responses that help eliminate or inhibit the growth of abnormal cells. This precise targeting makes antibody therapy a promising approach for treating various diseases, offering a tailored and effective strategy in the field of medical intervention and personalized medicine.
COVID-19 Impact
While the influence of COVID-19 had been mostly negative in several areas, the antibody therapy industry gained considerable momentum due to a spike in demand for the treatment development of COVID-19. Several companies commenced their R&D at a faster pace for the development of diagnostic and treatment related to COVID. The FDA and other organizations of various countries gave emergency use authorizations (EUAs) for the use of anti-SARS-CoV-2 mAb and other antibody therapy for the treatment of mild to moderate COVID-19 infection. Hence, COVID-19 showed a positive effect on the market of antibody therapy in 2020.
Antibody Therapy Market Trends
Antibody Therapy Market Analysis
The market based on type is segmented into monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs). The monoclonal antibodies (mAbs) segment is further split into oncology, autoimmune diseases, infectious diseases, and other monoclonal antibodies. The mAbs segment is expected to exhibit 11.7% CAGR during the forecast period.
The antibody therapy market based on end-use is categorized into hospitals, specialty centers, and other end-users. The hospitals segment held the major share of 47.6% in 2022.
The North America antibody therapy market is expected surpass the revenue USD 284.0 billion by 2032.
Antibody Therapy Market Share
The key players are actively engaged in strategic collaborations, product launches, and acquisitions to strengthen their market position. The market also witnesses a surge in biosimilar competition, intensifying rivalry. Strong R&D initiatives, coupled with regulatory approvals, show the dynamic competition, fostering advancements in antibody therapies and shaping the market's evolving competitive landscape.
Market players operating in the antibody therapy is as mentioned below:
Antibody Therapy Industry News:
The global antibody therapy market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2018 to 2032 for the following segments:
Click here to Buy Section of this Report
By Type 2018 – 2032 (USD Million)
By End-use 2018 – 2032 (USD Million)
The above information is provided for the following regions and countries: